{"schema_version":"secwatch.filing_event.v1","accession":"0000929638-23-003423","form_type":"8-K","ticker":"ENGN","cik":"0001980845","company_name":"enGene Therapeutics Inc.","filed_at":"2023-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.498299+00:00","generated_at":"2026-06-07T13:42:55.706813+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"enGene appoints Ryan Daws as CFO with $440K salary, 232K stock option grant","bullets":["Ryan Daws appointed CFO effective Nov 27, 2023; base salary $440,000, target bonus 40%.","One-time sign-on bonus of $143,500 payable Jan 2024; must repay if leaves within 1 year or terminated for cause.","Granted option for 232,000 common shares at fair market value on Nov 30, 2023; 25% vests on 1st anniversary, monthly thereafter.","Severance on termination without cause or for good reason: 12 months base salary, COBRA, prorated bonus, and partial equity acceleration.","On change in control termination: full equity acceleration plus 12 months base and target bonus."],"urls":{"canonical":"https://secwatch.observer/filing/0000929638-23-003423","json":"https://secwatch.observer/filing/0000929638-23-003423.json","markdown":"https://secwatch.observer/filing/0000929638-23-003423.md","text":"https://secwatch.observer/filing/0000929638-23-003423.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1980845/000092963823003423/0000929638-23-003423-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1980845/000092963823003423/a8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T13:42:55.706813+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"96b4445db6","claim":"Ryan Daws was appointed as Chief Financial Officer at enGene Therapeutics Inc..","evidence_excerpt":"On December 13, 2023, Ryan Daws, Chief Financial Officer of enGene Holdings Inc. (the “Company”), entered into an Executive Employment Agreement with enGene USA, Inc. (“enGene USA”), effective as of November 27, 2023 (the “Daws Employment Agreement”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1980845/000092963823003423/0000929638-23-003423-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}